Literature DB >> 11053086

Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumour necrosis factor receptor type I: a clinical update.

M W Davis1, U Feige, A M Bendele, S W Martin, C K Edwards.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11053086      PMCID： PMC1766629          DOI： 10.1136/ard.59.suppl_1.i41

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  10 in total

1.  Spinal epidural hematoma complicating active systemic lupus erythematosus.

Authors:  B Goker; J A Block
Journal:  Arthritis Rheum       Date:  1999-03

2.  Phase I/II trial of recombinant methionyl human tumor necrosis factor binding protein PEGylated dimer in patients with active refractory rheumatoid arthritis.

Authors:  L W Moreland; D P McCabe; J R Caldwell; M Sack; M Weisman; G Henry; J E Seely; S W Martin; C L Yee; A M Bendele; J L Frazier; T Kohno; M E Cosenza; S A Lyons; J M Dayer; A M Cohen; C K Edwards
Journal:  J Rheumatol       Date:  2000-03       Impact factor: 4.666

3.  Effects of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) alone and in combination with methotrexate in adjuvant arthritic rats.

Authors:  A M Bendele; J McComb; T Gould; J Frazier; E Chlipala; J Seely; G Kieft; C K Edwards
Journal:  Clin Exp Rheumatol       Date:  1999 Sep-Oct       Impact factor: 4.473

Review 4.  PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases.

Authors:  C K Edwards
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

5.  Combination benefit of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) and dexamethasone or indomethacin in adjuvant arthritic rats.

Authors:  A M Bendele; J McComb; T Gould; J Frazier; E S Chlipala; J Seely; G Kieft; J Wolf; C K Edwards
Journal:  Inflamm Res       Date:  1999-08       Impact factor: 4.575

6.  Antiarthritic activity of soluble tumor necrosis factor receptor type I forms in adjuvant arthritis: correlation of plasma levels with efficacy.

Authors:  J McComb; T Gould; E Chlipala; G Sennelo; J Frazier; G Kieft; J Seely; C K Edwards; A Bendele
Journal:  J Rheumatol       Date:  1999-06       Impact factor: 4.666

7.  Pharmacokinetics, immunogenicity, and efficacy of dimeric TNFR binding proteins in healthy and bacteremic baboon.

Authors:  C C Solorzano; A Kaibara; P J Hess; P D Edwards; R Ksontini; A Abouhamze; S McDaniel; J Frazier; D Trujillo; G Kieft; J Seely; T Kohno; M E Cosenza; M Clare-Salzler; S L MacKay; S W Martin; L L Moldawer; C K Edwards
Journal:  J Appl Physiol (1985)       Date:  1998-04

8.  Reduction of arthritis and pneumonitis in motheaten mice by soluble tumor necrosis factor receptor.

Authors:  X Su; T Zhou; P Yang; C K Edwards; J D Mountz
Journal:  Arthritis Rheum       Date:  1998-01

9.  Use of recombinant human soluble TNF receptor in anorectic tumor-bearing rats.

Authors:  G F Torelli; M M Meguid; L L Moldawer; C K Edwards; H J Kim; J L Carter; A Laviano; F Rossi Fanelli
Journal:  Am J Physiol       Date:  1999-09

10.  Different roles of tumour necrosis factor alpha and interleukin 1 in murine streptococcal cell wall arthritis.

Authors:  S Kuiper; L A Joosten; A M Bendele; C K Edwards; O J Arntz; M M Helsen; F A Van de Loo; W B Van den Berg
Journal:  Cytokine       Date:  1998-09       Impact factor: 3.861
  10 in total
  2 in total

Review 1.  Perspectives for TNF-alpha-targeting therapies.

Authors:  Hanns-Martin Lorenz; Joachim R Kalden
Journal:  Arthritis Res       Date:  2002-05-09

Review 2.  A New Venue of TNF Targeting.

Authors:  Sophie Steeland; Claude Libert; Roosmarijn E Vandenbroucke
Journal:  Int J Mol Sci       Date:  2018-05-11       Impact factor: 5.923
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.